Mereo Biopharma Stock Price, News & Analysis

Mereo BioPharma Group (NASDAQ: MREO) announced its 2021 financial results, revealing a revenue of £36.5 million from a licensing agreement with Ultragenyx. The company reported a net profit of £12.7 million, a significant improvement from the £163.6 million loss in 2020, driven by a £40 million gain from financial instruments. R&D expenses increased by 44% to £23.6 million, mainly due to advancements in the etigilimab program. Noteworthy clinical updates include promising interim results from the ACTIVATE study and FDA orphan drug designation for alvelestat.

Mereo BioPharma Group plc (NASDAQ: MREO) announced a virtual R&D Day on March 14, 2022, focusing on its alvelestat (MPH966) program. This session will detail ongoing Phase 2 studies for treating alpha-1 antitrypsin deficiency (AATD)-related lung disease and updates on the investigator-sponsored Phase 1b/2 studies for Bronchiolitis Obliterans post-hematopoietic stem cell transplantation and hospitalized COVID-19 patients. Key opinion leaders and company management will present during the two-hour event. The audio will be accessible live and archived on the company's website.

Mereo BioPharma Group plc (NASDAQ: MREO) has appointed Anne Hyland to its Board of Directors and the Audit and Risk Committee, effective immediately. With over 30 years of financial expertise in the biopharmaceutical sector, Hyland's experience includes her role as CFO at Kymab Group Limited, which was acquired by Sanofi for $1.1 billion in 2021. CEO Denise Scots-Knight expressed enthusiasm for Hyland's operational insight, citing the potential impact on Mereo's ongoing development in oncology and rare diseases.

Mereo BioPharma Group (NASDAQ: MREO) announced that CEO Dr. Denise Scots-Knight will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 8:00 AM ET. The event will be accessible via a live audio webcast on Mereo's investor website, and an archived replay will be available for two weeks post-event. Mereo focuses on developing therapeutics for oncology and rare diseases, with several clinical-stage product candidates including etigilimab and navicixizumab, as well as rare disease treatments like alvelestat.

Mereo BioPharma announced encouraging results from its Phase 1b/2 trial of alvelestat in hospitalized COVID-19 patients. The trial showed that patients receiving alvelestat, alongside standard care, experienced a more rapid improvement in the WHO Disease Severity score compared to those on placebo. A total of 15 patients were involved, and no safety signals were reported, though headaches were noted more frequently in the alvelestat group. Results suggest that alvelestat could provide clinical benefits beyond standard COVID-19 treatments.

Mereo BioPharma presented initial data from a study of alvelestat at the 63rd American Society of Hematology Annual Meeting. The Phase 1b/2 trial involves patients with bronchiolitis obliterans syndrome (BOS) post-hematopoietic stem cell transplantation, showing that treatment with alvelestat was well-tolerated and led to a decrease in biomarkers related to elastase activity. Out of seven patients, six had stable or improved lung disease, with some demonstrating significant symptom improvement. The findings suggest alvelestat's potential to impact lung fibrosis in BOS.

Mereo BioPharma (NASDAQ: MREO) reported interim efficacy data from its ACTIVATE study of etigilimab, an anti-TIGIT antibody, in combination with nivolumab for advanced solid tumors. Among 15 patients evaluated, one complete response was observed in cervical cancer, one partial response in ovarian cancer, and four cases of stable disease. The study demonstrated a favorable safety profile, with no new safety signals. The trial aims to enroll around 125 patients. Further updates are anticipated in 2022.

Mereo BioPharma Group plc (NASDAQ: MREO) announced that CEO Dr. Denise Scots-Knight will present at two investor conferences. The Jefferies London Healthcare Conference features an in-person fireside chat on November 17 at 10:00 a.m. GMT. The Piper Sandler 33rd Annual Virtual Healthcare Conference will have an on-demand presentation available starting November 22 at 10:00 a.m. ET. Both sessions can be accessed via the Investors section of Mereo's website, with replays available for two weeks. Mereo focuses on oncology and rare diseases, with several clinical-stage product candidates.

Mereo BioPharma Group (NASDAQ: MREO) announced the upcoming presentation of data from a study on alvelestat for treating Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting from December 11-14, 2021. The study involved seven BOS patients post-hematopoietic stem cell transplantation, revealing that alvelestat consistently suppressed biomarkers of elastase activity and collagen turnover in six patients. This indicates a potential impact on progressive lung fibrosis. The poster presentation will happen on December 11, 2021, featuring results that highlight the drug’s therapeutic promise.